These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11965921)

  • 21. FDA notifications. FDA tentatively approves fixed-dose lamivudine/zidovudine.
    AIDS Alert; 2010 Dec; 25(12):142-3. PubMed ID: 21328815
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA notifications. Complera approved.
    AIDS Alert; 2011 Nov; 26(11):130-1. PubMed ID: 22164521
    [No Abstract]   [Full Text] [Related]  

  • 23. I want a new drug. An overview of three new anti-HIV drugs.
    Simmons P
    Res Initiat Treat Action; 1998 Jun; 4(3):9-11. PubMed ID: 11365539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA approves new versions of two HIV/AIDS drugs.
    HIV Clin; 2000; 12(2):11. PubMed ID: 11810829
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA approves generic abacavir sulfate tablets.
    AIDS Alert; 2006 Dec; 21(12):139-40. PubMed ID: 17233093
    [No Abstract]   [Full Text] [Related]  

  • 26. Efavirenz newly approved.
    Newsline People AIDS Coalit N Y; 1998; ():31. PubMed ID: 11367501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadened access to Sustiva.
    Bornhoeft MA
    Body Posit; 1998 Jan; 11(1):13. PubMed ID: 11365007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drug approved.
    AIDS Policy Law; 1998 Oct; 13(18):12. PubMed ID: 11365934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA notifications. FDA approves generic stavudine.
    AIDS Alert; 2009 Mar; 24(3):34. PubMed ID: 19441156
    [No Abstract]   [Full Text] [Related]  

  • 30. Efavirenz reclassified as FDA pregnancy category D.
    Mofenson LM
    AIDS Clin Care; 2005 Feb; 17(2):17. PubMed ID: 15754452
    [No Abstract]   [Full Text] [Related]  

  • 31. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
    Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA notifications. Tentative approval granted for lamivudine/stavudine.
    AIDS Alert; 2008 Aug; 23(8):92-3. PubMed ID: 18727174
    [No Abstract]   [Full Text] [Related]  

  • 33. Sparing the protease for some spoils the price for all.
    Grinberg L
    GMHC Treat Issues; 1998 Sep; 12(9):1-2. PubMed ID: 11365802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA notifications. FDA approves generic lamivudine.
    AIDS Alert; 2008 Dec; 23(12):142. PubMed ID: 19110688
    [No Abstract]   [Full Text] [Related]  

  • 35. Now approved: Sustiva in combination offers patients a new first-line therapy.
    Fac Notes (New Orleans La); 1998; 10(6):10. PubMed ID: 11366140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA issues labeling changes for efavirenz.
    González-Lahoz J
    AIDS Rev; 2004; 6(3):181-2. PubMed ID: 15595435
    [No Abstract]   [Full Text] [Related]  

  • 38. Adherence strategies. FDA approves ddI generic version.
    AIDS Alert; 2006 Nov; 21(11):131. PubMed ID: 17111491
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA notifications. FDA tentatively approves generic lamivudine.
    AIDS Alert; 2007 May; 22(5):57. PubMed ID: 17580368
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA notifications. FDA approved pediatric efficacy supplement for Retrovir syrup.
    AIDS Alert; 2008 Nov; 23(11):128. PubMed ID: 19043870
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.